IIFL View
Go
  • Thyrocare Tech.

    Thyrocare’s high B2B exposure helps it procure reagent at ~70% discount, thereby protecting margins. The 24% revenue contribution by B2C business also offers higher profitability. A likely shift in Indian diagnostic industry, from unorganised to organ...

    Buy Reco. Price: 554.00

  • Abbott India

    We project Abbott India’s revenue/PAT CAGR of 16%/21%, respectively, over FY18-20E owing to (a) new product launches in India, (b) entry in high-margin vaccine segment, and (c) high brand recall in existing products. The company also distributes Novo ...

    Accumulate Reco. Price: 7,590.00

  • Mahindra CIE

    MCIE has restructured and consolidated its business over last three years and will now enter growth phase. The recent acquisition of Bill Forge added new products to MCIE’s portfolio. The European operations have also picked up pace since the continen...

    Buy Reco. Price: 263.00

  • Biocon

    Biocon’s early entry in the biosimilars business is a long term positive for the company. Biocon-Mylan has recently received an approval for Trastuzumab and Pegfilgrastim in US and we expect approval to 3-4 more biosimilars in 2018/2019 across US and ...

    Buy Reco. Price: 625.00

  • Merck

    Merck’s revenue and PAT, over CY17-CY19E is expected to grow at a CAGR of 17%/40% respectively due to the strong brand value (Evion, Neurobion and Livogen) and its well balanced portfolio in pharma and chemicals. The company has debt free balance shee...

    Buy Reco. Price: 3,028.00

  • G S F C

    GSFC’s spread on caprolactum stood at ~US$1,250/MT in Q2FY19 which is expected to remain in the range of US$1,100-1,200/MT during FY19E. Further, commissioning of 40,000MTPA melamine plant by Q4FY19 with strong ramp-up (utilization at ~80% by the end ...

    Buy Reco. Price: 106.00

  • Max India

    Its hospital business would benefit from expansion of bed capacity from 2,570 beds in FY18 to 5,810 beds by FY23E. Company focuses on improving its specialty healthcare services, which provides higher margins vs. low margin primary healthcare services. Its ...

    Accumulate Reco. Price: 73.00

  • M & M

    M&M reported steady Q2FY19 with 9% yoy and 5% yoy revenue growth for automotive and tractor segments respectively. Management has slightly downgraded FY19 tractor volume growth guidance to 12% against 12-14% guided earlier. Margin for automotive seg...

    Buy Reco. Price: 770.45

  • FDC

    FDC has mainly branded business in India. Two of its products i.e. Zifi and Electral are among the top 300 brands in the Indian pharma industry. Its top five brands contribute 35-40% of total revenue. FDC enjoys strong brand recall, debt free balance sheet,...

    Buy Reco. Price: 191.75

  • CRISIL

    CRISIL is currently facing headwinds in most of its businesses. Research and Information Services segment has seen single digit yoy growth successively for past six quarters, affected by implementation of MiFID II (Markets in Financial Instruments Directive...

    Reduce Reco. Price: 1,496.95